This site is intended for health professionals only

Published on 13 November 2008

Share this story:
Twitter
LinkedIn

HIV vaccine trial a total failure

teaser

The total failure of a “promising” HIV vaccine has led to questions being asked about the use of animals in the development of such treatments.

The Step Study clinical trial has shown that MRKAd5 HIV-1 gag/pol/nef failed completely to protect against HIV. In fact, some people given the vaccine had a higher rate of infection than those receiving the placebo.

Prior to the trial, the vaccine – made by the pharmaceutical company Merck – had been tested on monkeys exposed to a simian-HIV (SHIV) viral infection.

SHIV is a mixture of SIV (simian immunodeficiency virus) and some components of HIV (human immunodeficiency virus).

The vaccine is supposed to trigger a protective response by “killer” cytotoxic T-cells, white blood cells that are a key element of the immune system.

In an accompanying comment in The Lancet, Dr Merlin Robb, from the US Military HIV Research Program in Rockville, Maryland, said: “The Step results have profoundly affected the HIV-vaccine development field. The predictive value of the non-human SHIV-challenge model is not supported by this experience.

“The failure of Step has not closed the door on the T-cell vaccine concept. However, the reflection it has caused might be a crucial step towards an HIV vaccine.”

Copyright Press Association 2008

The Lancet



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn